We draw inspiration from the biodiversity of nature: from microorganisms, their specific abilities and the enzymes that support these abilities.
We offer innovative biological solutions and products based on microorganisms and enzymes. These enable industry to improve products, make manufacturing processes more efficient and increase the sustainability of products and processes.
We follow established national and international guidelines in our strategy for sustainable corporate development and reporting.
Management Statement 6M 2024/25
IR Presentation May 2025
Management Statement 3M 2024/25
Management Statement 12M 2023/24
IR Presentation "Deutsches Eigenkapitalforum 2024"
Management Statement Akribion Therapeutics Agreement
Management Statement Royalty Purchase Agreement
IR Presentation "Baader Investment Conference 2024"
Management Statement 9M 2023/24
Management Statement 6M 2023/24
Elevator Pitch from CFO Michael Schneiders (Date of recording: June 4, 2025)
CFO Michael Schneiders: Financial Results H1 2024/25 | Innovation Momentum and Strategic Focus
CFO Michael Schneiders: Financial Results Q1 2024/25 | Growth, Innovation & Outlook
CFO Michael Schneiders: Financial Performance and Growth Strategy of BRAIN Biotech AG
All older videos can be found on the SEAT11a platform.
Investor Relations
Martina Schuster
ir@brain-biotech.com
+49 6251 9331 69